Fulcrum Therapeutics Promotes Diego Cadavid, M.D., to Senior Vice President, Clinical Development

August 14, 2018

Cambridge, Mass., August 14, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, today announced the promotion of Diego Cadavid, M.D., formerly Vice President, Clinical Development, to Senior Vice President, Clinical Development.

Cadavid has been a valued member of the Fulcrum team for nearly two years. He joined Fulcrum in September 2016, bringing with him 17 years of experience in academic and biotechnology research, primarily focused on neurological and central nervous system (CNS) disorders. Cadavid spent nearly a decade at Biogen, where he served as Senior Medical Director of the Multiple Sclerosis Clinical Development Group and led the CNS Remyelination Team. He also spent much of that time as a consultant at the Center for Immunology and Inflammatory Diseases at Massachusetts General Hospital.

Prior to working at Biogen, Cadavid was an Associate Professor of Neurology and Neuroscience at Rutgers-New Jersey Medical School, where he conducted research on spirochetal brain infections and multiple sclerosis. Cadavid has an M.D. from Universidad Javeriana in Bogota, Colombia., and completed postdoctoral research at the University of Texas Health Science Center in San Antonio. He also underwent Neurology Residency Training at Georgetown University Hospitals and was a Neuropathology Fellow at the Armed Forces Institute of Pathology.

“I am proud to be a part of Fulcrum’s leadership team as we explore transformative therapies for rare genetic diseases,” Cadavid said. “As Senior Vice President of Clinical Development, I plan to redouble my efforts to help move treatments for disorders with high unmet need, such as FSHD, toward the clinic.”

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.


Sarah Sutton
Ten Bridge Communications
[email protected]